Skip to main content
SpringerLink
Log in
Book cover

Ovarian Cancer pp 331–351Cite as

Ovarian Cancer- Associated Proteinases

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 107))

Abstract

Ovarian carcinoma is the leading cause of death from gynecologic malignancies and the fourth most common cause of cancer related deaths among North American women. Approximately one out of every 70 women is estimated to develop ovarian cancer and one in 100 will die from the disease. A major cause of the high mortality of ovarian cancer is the lack of proper diagnostic tools for early detection when the tumor is still confined to the ovaries (FIGO stage I). Approximately 75% of patients are diagnosed with pre-existing disseminated intra-abdominal metastases (FIGO stage III or IV). Although the 5-year survival rate for cancer localized to the ovary can be as high as 90%, women with distant metastases have a less than 20% survival rate (Hoskins, 1995). Thus, a more detailed understanding of the factors that control ovarian cancer invasion and metastasis may have a significant impact on patient survival.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Afzal, S., Lalani el, N., Foulkes, W. D., Boyce, B., Tickle, S., Cardillo, M. R., Baker, T., Pignatelli, M., and Stamp, G. W. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996; 74: 406–21.

    CAS  PubMed  Google Scholar 

  • Afzal, S., Lalani, E. N., Poulsom, R., Stubbs, A., Rowlinson, G., Sato, H., Seiki, M., and Stamp, G. W. MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 1998; 29: 155–65.

    Article  CAS  PubMed  Google Scholar 

  • Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1–22.

    Article  CAS  PubMed  Google Scholar 

  • Astedt, B., Svanberg, L., and Nilsson, I. M. Fibrin degradation products and ovarian tumours. Br Med J 1971; 4: 458–9.

    Article  CAS  PubMed  Google Scholar 

  • Band, V., Karlan, B. Y., Zurawski, V. R., Jr., and Littlefield, B. A. Simultaneous stimulation of urokinase and tissue-type plasminogen activators by phorbol esters in human ovarian carcinoma cells. J Cell Physiol 1989; 138: 106–14.

    Article  CAS  PubMed  Google Scholar 

  • Bartlett, J. M., Langdon, S. P., Simpson, B. J., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W. N., Williams, A. R., Lessells, A. M., et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br J Cancer 1996; 73: 301–6.

    Article  CAS  PubMed  Google Scholar 

  • Beattie, G. J., and Smyth, J. F. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 1998; 4: 1899–902.

    CAS  PubMed  Google Scholar 

  • Casslen, B., Gustaysson, B., and Astedt, B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur J Cancer 1991; 27: 1445–8.

    Article  CAS  PubMed  Google Scholar 

  • Chambers, S. K., Wang, Y., Gertz, R. E., and Kacinski, B. M. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. Cancer Res 1995; 55: 1578–85.

    CAS  PubMed  Google Scholar 

  • Conese, M., and Blasi, F. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol Chem Hoppe Seyler 1995; 376, 143–55.

    CAS  PubMed  Google Scholar 

  • Crickard, K., Niedbala, M. J., Crickard, U., Yoonessi, M., Sandberg, A. A., Okuyama, K., Bernacki, R. J., and Satchidanand, S. K. Characterization of human ovarian and endometrial carcinoma cell lines established on extracellular matrix. Gynecol Oncol 1989; 32: 163–73.

    Article  CAS  PubMed  Google Scholar 

  • Davies, B., Brown, P. D., East, N., Crimmin, M. J., and Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53 (15): 2087–91.

    CAS  PubMed  Google Scholar 

  • De Nictolis, M., Garbisa, S., Lucarini, G., Goteri, G., Masiero, L., Ciavattini, A., Garzetti, G. G., Stetler-Stevenson, W. G., Fabris, G., Biagini, G., and Prat, J. 72-kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study. Int J Gynecol Pathol 1996; 15: 102–9.

    Google Scholar 

  • Dolo, V., D’Ascenzo, S., Violini, S., Pompucci, L., Festuccia, C., Ginestra, A., Vittorelli, M. L., Canevari, S., and Pavan, A. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 1999; 17: 131–40.

    Article  CAS  PubMed  Google Scholar 

  • d’Ortho, M. P., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilovic, J., Smith, B., Timpl, R., Zardi, L., and Murphy, G. Membrane-type matrix metalloproteinases I and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751–7.

    Article  PubMed  Google Scholar 

  • Dumler, I., Petri, T., and Schleuning, W. D. Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett 1994; 343: 103–6.

    Article  CAS  PubMed  Google Scholar 

  • Ellerbroek, S.M., Halbleib, J.M., Benavidez, M., Warmka, J.K., Wattenberg, E.V., Stack, M.S., and Hudson, L.G. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Research 2001; in press.

    Google Scholar 

  • Ellerbroek, S. M., Fishman, D. A., Kearns, A. S., Bafetti, L. M., and Stack, M. S. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through betal integrin. Cancer Res 1999; 59: 1635–41.

    CAS  PubMed  Google Scholar 

  • Ellerbroek, S. M., Hudson, L. G., and Stack, M. S. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 1998; 78: 331–7.

    Article  CAS  PubMed  Google Scholar 

  • Fang, X., Gaudette, D., Fumi, T., Mao, M., Estrella, V., Eder, A., Pustilnik, T., Sasagawa, T., Lapushin, R., Yu, S., et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci 2000; 905: 188–208.

    Article  CAS  PubMed  Google Scholar 

  • Fischer, K., Lutz, V., Wilhelm, O., Schmitt, M., Graeff, H., Heiss, P., Nishiguchi, T., Harbeck, N., Kessler, H., Luther, T., et al. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett 1998; 438: 101–5.

    Article  CAS  PubMed  Google Scholar 

  • Fishman, D. A., Bafetti, L. M., and Stack, M. S. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 1996; 16: 150–9.

    CAS  PubMed  Google Scholar 

  • Fishman, D. A., Bafetti, L. M., Banionis, S., Kearns, A. S., Chilukuri, K., and Stack, M. S. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997; 80: 1457–63.

    Article  CAS  PubMed  Google Scholar 

  • Fishman, D. A., Kearns, A., Chilukuri, K., Bafetti, L. M., O’Toole, E. A., Georgacopoulos, J., Ravosa, M. J., and Stack, M. S. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2betal-integrin-mediated interaction with type I collagen. Invasion Metastasis 1998; 18: 15–26.

    Article  CAS  PubMed  Google Scholar 

  • Fishman, D. A., Kearns, A., Larsh, S., Enghild, J. J., and Stack, M. S. Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment. Biochem J 1999; 341: 765–9.

    Article  CAS  PubMed  Google Scholar 

  • Fishman, D.A., Liu, Y., Ellerbroek, S.M. and Stack, M.S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Research 2001; in press.

    Google Scholar 

  • Furui, T., LaPushin, R., Mao, M., Khan, H., Watt, S. R., Watt, M. A., Lu, Y., Fang, X., Tsutsui, S., Siddik, Z. H., et al. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 1999; 5: 4308–18.

    CAS  PubMed  Google Scholar 

  • Garzetti, G. G., Ciavattini, A., Lucarini, G., Goteri, G., de e Nictolis, M., Garbisa, S., Masiero, L., Romanini, C., and Graziella, B. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 1995; 15: 2799–804.

    CAS  PubMed  Google Scholar 

  • Garzetti, G. G., Ciavattini, A., Lucarini, G., Goteri, G., Romanini, C., and Biagini, G. Increased serum 72 KDa metalloproteinase in serous ovarian tumors: comparison with CA 125. Anticancer Res 1996; 16: 2123–7.

    CAS  PubMed  Google Scholar 

  • Garzetti, G. G., Ciavattini, A., Lucarini, G., Pugnaloni, A., De Nictolis, M., Amati, S., Romanini, C., and Biagini, G. Expression of vascular endothelial growth factor related to 72- kilodalton metalloproteinase immunostaining in patients with serous ovarian tumors. Cancer 1999; 85: 2219–25.

    Article  CAS  PubMed  Google Scholar 

  • Ginestra, A., Miceli, D., Dolo, V., Romano, F. M., and Vittorelli, M. L. Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res 1999; 19: 3439–45.

    CAS  PubMed  Google Scholar 

  • Hafter, R., Klaubert, W., Gollwitzer, R., von Hugo, R., and Graeff, H. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. Thromb Res 1984; 35: 53–64.

    Article  CAS  PubMed  Google Scholar 

  • Harvey, W., and Amlot, P. L. Collagen production by human mesothelial cells in vitro, J Pathol 1983; 139: 337–47.

    Article  CAS  PubMed  Google Scholar 

  • Hirahara, F., Miyagi, Y., Miyagi, E., Yasumitsu, H., Koshikawa, N., Nagashima, Y., Kitamura, H., Minaguchi, H., Umeda, M., and Miyazaki, K. Trypsinogen expression in human ovarian carcinomas. Int J Cancer 1995; 63: 176–81.

    Article  CAS  PubMed  Google Scholar 

  • Holst-Hansen, C., Hamers, M. J., Johannessen, B. E., Brunner, N., and Stephens, R. W. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies. Br J Cancer 1999; 81: 203–11.

    Article  CAS  PubMed  Google Scholar 

  • Hoskins, W. J. Prospective on ovarian cancer: why prevent? J Cell Biochem Suppl 1995; 23: 189–99.

    Article  CAS  PubMed  Google Scholar 

  • Huang, L. W., Garrett, A. P., Bell, D. A., Welch, W. R., Berkowitz, R. S., and Mok, S. C. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 2000; 77: 369–76.

    Article  CAS  PubMed  Google Scholar 

  • Johansson, N., Vaalamo, M., Grenman, S., Hietanen, S., Klemi, P., Saarialho-Kere, U., and Kahari, V. M. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999; 154: 469–80.

    Article  CAS  PubMed  Google Scholar 

  • Kanamori, Y., Matsushima, M., Minaguchi, T., Kobayashi, K., Sagae, S., Kudo, R., Terakawa, N., and Nakamura, Y. Correlation between expression of the matrix metalloproteinase-I

    Google Scholar 

  • gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 1999; 59: 4225–7.

    Google Scholar 

  • Kanemoto, T., Martin, G. R., Hamilton, T. C., and Fridman, R. Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR3) with a reconstituted basement membrane (Matrigel). Invasion Metastasis 1991; 11: 84–92.

    CAS  PubMed  Google Scholar 

  • Karlan, B. Y., Amin, W., Band, V., Zurawski, V. R., Jr., and Littlefield, B. A. Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol 1988; 31: 103–12.

    Article  CAS  PubMed  Google Scholar 

  • Karlan, B. Y., Rivero, J. A., Crabtree, M. E., and Littlefield, B. A. Different mechanisms contribute to simultaneous inhibition of urokinase and tissue-type plasminogen activators by glucocorticoids in human ovarian carcinoma cells. Mol Endocrinol 1989; 3: 1006–13.

    Article  CAS  PubMed  Google Scholar 

  • Kikkawa, F., Tamakoshi, K., Nawa, A., Shibata, K., Yamagata, S., Yamagata, T., and Suganuma, N. Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues. Cancer Lett 1997; 120: 10915.

    Article  Google Scholar 

  • Kobayashi, H., Fujie, M., Shinohara, H., Ohi, H., Sugimura, M., and Terao, T. Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells, Int J Cancer 1994; 57: 378–84.

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi, H., Moniwa, N., Sugimura, M., Shinohara, H., Ohi, H., and Terao, T. Increased cell-surface urokinase in advanced ovarian cancer. Jpn J Cancer Res 1993; 84: 633–40.

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi, H., Moniwa, N., Sugimura, M., Shinohara, H., Ohi, H., and Terao, T. Effects of membrane-associated cathepsin B on the activation of receptor-bound prourokinase and subsequent invasion of reconstituted basement membranes. Biochim Biophys Acta 1993; 1178: 55–62.

    Article  CAS  PubMed  Google Scholar 

  • Kobayashi, H., Ohi, H., Sugimura, M., Shinohara, H., Fujii, T., and Terao, T. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 1992; 52: 3610–4.

    CAS  PubMed  Google Scholar 

  • Kobayashi, H., Shinohara, H., Ohi, H., Sugimura, M., Terao, T., and Fujie, M. Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clin Exp Metastasis 1994; 12: 117–28.

    Article  CAS  PubMed  Google Scholar 

  • Kohn, E. C., Jacobs, W., Kim, Y. S., Alessandro, R., Stetler-Stevenson, W. G., and Liotta, L. A. Calcium influx modulates expression of matrix metalloproteinase-2 (72- kDa type IV collagenase, gelatinase A). J Biol Chem 1994; 269: 21505–11.

    CAS  PubMed  Google Scholar 

  • Kuhn, W., Pache, L., Schmalfeldt, B., Dettmar, P., Schmitt, M., Janicke, F., and Graeff, H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 1994; 55: 401–9.

    Article  CAS  PubMed  Google Scholar 

  • Leber, T. M., and Balkwill, F. R. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer 1998; 78: 724–32.

    Article  CAS  PubMed  Google Scholar 

  • Liotta, L. A., Rao, C. N., and Wewer, U. M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986; 55: 1037–57.

    Article  CAS  PubMed  Google Scholar 

  • Macaulay, V. M., O’Byrne, K. J., Saunders, M. P., Braybrooke, J. P., Long, L., Gleeson, F., Mason, C. S., Harris, A. L., Brown, P., and Talbot, D. C. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 1999; 5: 513–20.

    CAS  PubMed  Google Scholar 

  • Malfetano, J., Teng, N., and Barter, J. Marimastat in patients with advanced cancer of the

    Google Scholar 

  • ovary: A dose-finding study. Proc Am Soc Clin Oncol 1997; 16: 373a.

    Google Scholar 

  • Massova, I., Kotra, L. P., Fridman, R., and Mobashery, S. Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 1998; 12: 1075–95.

    CAS  PubMed  Google Scholar 

  • Meden, H., Marx, D., Rath, W., Kron, M., Fattahi-Meibodi, A., Hinney, B., Kuhn, W., and Schauer, A. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994; 13: 45–53.

    Article  CAS  PubMed  Google Scholar 

  • Medl, M., Ogris, E., Peters-Engl, C., and Leodolter, S. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer. Br J Cancer 1995; 71: 1051–4.

    Article  CAS  PubMed  Google Scholar 

  • Mirshahi, S. S., Lounes, K. C., Lu, H., Pujade-Lauraine, E., Mishal, Z., Benard, J., Bemadou, A., Soria, C., and Soria, J. Defective cell migration in an ovarian cancer cell line is associated with impaired urokinase-induced tyrosine phosphorylation. FEBS Lett 1997; 411: 322–6.

    Article  CAS  PubMed  Google Scholar 

  • Miyagi, E., Yasumitsu, H., Hirahara, F., Minaguchi, H., Koshikawa, N., Miyazaki, K., and Umeda, M. Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells. Jpn J Cancer Res 1995; 86: 568–76.

    Article  CAS  PubMed  Google Scholar 

  • Mondino, A., Resnati, M., and Blasi, F. Structure and function of the urokinase receptor. Thromb Haemost 1999; 82 Suppl 1: 19–22.

    Google Scholar 

  • Moore, D. H., Allison, B., Look, K. Y., Sutton, G. P., and Bigsby, R. M. Collagenase expression in ovarian cancer cell lines. Gynecol Oncol 1997; 65: 78–82.

    Article  CAS  PubMed  Google Scholar 

  • Mort, J. S., Leduc, M., and Recklies, A. D. A latent thiol proteinase from ascitic fluid of patients with neoplasia. Biochim Biophys Acta 1981; 662: 173–80.

    Article  CAS  PubMed  Google Scholar 

  • Moser, T. L., Young, T. N., Rodriguez, G. C., Pizzo, S. V., Bast, R. C., Jr., and Stack, M. S. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994; 56: 552–9.

    Article  CAS  PubMed  Google Scholar 

  • Murdoch, W. J. Proteolytic and cellular death mechanisms in ovulatory ovarian rupture. Biol Signals Recept 2000; 9: 102–14.

    Article  CAS  PubMed  Google Scholar 

  • Nagase, H., and Woessner, J. F., Jr.. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–4.

    Article  CAS  PubMed  Google Scholar 

  • Naylor, M. S., Stamp, G. W., Davies, B. D., and Balkwill, F. R. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994; 58: 50–6.

    Article  CAS  PubMed  Google Scholar 

  • Nelson, A. R., Fingleton, B., Rothenberg, M. L., and Matrisian, L. M. Matrix

    Google Scholar 

  • metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000; 18: 113549.

    Google Scholar 

  • Nemunaitis, J., Poole, C., Primrose, J., Rosemurgy, A., Malfetano, J., Brown, P., Berrington, A., Cornish, A., Lynch, K., Rasmussen, H., et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998; 4: 1101–9.

    CAS  PubMed  Google Scholar 

  • Niedbala, M. J., Madiyalakan, R., Matta, K., Crickard, K., Sharma, M., and Bernacki, R. J. Role of glycosidases in human ovarian carcinoma cell mediated degradation of subendothelial extracellular matrix. Cancer Res 1987; 47: 4634–41.

    CAS  PubMed  Google Scholar 

  • Ohuchi, E., Imai, K., Fujii, Y., Sato, H., Seiki, M., and Okada, Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997; 272: 2446–51.

    Article  CAS  PubMed  Google Scholar 

  • Patton, S. E., Martin, M. L., Nelsen, L. L., Fang, X., Mills, G. B., Bast, R. C., Jr., and Ostrowski, M. C. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 1998; 58: 2253–9.

    CAS  PubMed  Google Scholar 

  • Pedersen, N., Schmitt, M., Ronne, E., Nicoletti, M. I., Hoyer-Hansen, G., Conese, M., Giavazzi, R., Dano, K., Kuhn, W., Janicke, F., and et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993; 92: 2160–7.

    Article  CAS  PubMed  Google Scholar 

  • Poole, C., Adams, M., and Barley, V. A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor in patients with advanced ovarian cancer. Ann Oncol 1996; 7: 68.

    Google Scholar 

  • Pujade-Lauraine, E., Lu, H., Mirshahi, S., Soria, J., Soria, C., Bernadou, A., Kruithof, E. K., Lijnen, H. R., and Burtin, P. The plasminogen-activation system in ovarian tumors. Int J Cancer 1993; 55: 27–31.

    Article  CAS  PubMed  Google Scholar 

  • Pustilnik, T. B., Estrella, V., Wiener, J. R., Mao, M., Eder, A., Watt, M. A., Bast, R. C., Jr., and Mills, G. B. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 1999; 5: 3704–10.

    CAS  PubMed  Google Scholar 

  • Rabbani, S. A. Metalloproteases and urokinase in angiogenesis and tumor progression, In Vivo 1998; 12: 135–42.

    CAS  PubMed  Google Scholar 

  • Rasmussen, H. S., and McCann, P. P. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997; 75: 69–75.

    Article  CAS  PubMed  Google Scholar 

  • Scambia, G., Benedetti, P., Ferrandina, G., Battaglia, F., Baiocchi, G., and Mancuso, S. Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor. Br J Cancer 1991; 64: 182–4.

    Article  CAS  PubMed  Google Scholar 

  • Scambia, G., Panici, P. B., Ferrandina, G., Salerno, G., D’Agostino, G., Distefano, M., de Vincenzo, R., Ercoli, A., and Mancuso, S. Clinical significance of cathepsin D in primary ovarian cancer. Eur J Cancer 1994; 7: 935–40.

    Article  Google Scholar 

  • Shibata, K., Kikkawa, F., Nawa, A., Suganuma, N., and Hamaguchi, M. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines. Cancer Res 1997; 57: 5416–20.

    CAS  Google Scholar 

  • Shibata, K., Kikkawa, F., Nawa, A., Thant, A. A., Naruse, K., Mizutani, S., and Hamaguchi, M. Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells. Cancer Res 1998; 58: 900–3.

    CAS  PubMed  Google Scholar 

  • Shigemasa, K., Tanimoto, H., Sakata, K., Nagai, N., Pamiley, T. H., Ohama, K., and O’Brien, T. J. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol 2000; 17: 52–8.

    Article  CAS  PubMed  Google Scholar 

  • Sier, C. F., Stephens, R., Bizik, J., Mariani, A., Bassan, M., Pedersen, N., Frigerio, L., Ferrari, A., Dano, K., Brunner, N., and Blasi, F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843–9.

    CAS  PubMed  Google Scholar 

  • Tanimoto, H., Underwood, L. J., Shigemasa, K., Parmley, T. H., Wang, Y., Yan, Y., Clarke, J., and O’Brien, T. J. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment. Tumour Biol 1999; 20: 88–98.

    Article  CAS  PubMed  Google Scholar 

  • Tanimoto, H., Yan, Y., Clarke, J., Korourian, S., Shigemasa, K., Parmley, T. H., Parham, G. P., and O’Brien, T. J. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997; 57: 2884–7.

    CAS  PubMed  Google Scholar 

  • Ueda, M., Ueki, M., Terai, Y., Ueki, K., Kumagai, K., Fujii, H., Yoshizawa, K., and Nakajima, M. Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells. Gynecol Obstet Invest 1999; 48: 221–8.

    Article  CAS  PubMed  Google Scholar 

  • Wahlberg, K., Hoyer-Hansen, G., and Casslen, B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 1998; 58: 3294–8.

    CAS  PubMed  Google Scholar 

  • Westerlund, A., Apaja-Sarkkinen, M., Hoyhtya, M., Puistola, U., and Turpeenniemi-Hujanen, T. Gelatinase A-immunoreactive protein in ovarian lesions-prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999; 75: 91–8.

    Article  CAS  PubMed  Google Scholar 

  • Westerlund, A., Hujanen, E., Puistola, U., and Turpeenniemi-Hujanen, T. Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2). Gynecol Oncol 1997; 67: 76–82.

    Article  CAS  PubMed  Google Scholar 

  • Wilhelm, O., Hafter, R., Coppenrath, E., Pflanz, M. A., Schmitt, M., Babic, R., Linke, R., Gossner, W., and Graeff, H. Fibrin-fibronectin compounds in human ovarian tumor ascites and their possible relation to the tumor stroma. Cancer Res 1988; 48: 3507–14.

    CAS  PubMed  Google Scholar 

  • Wilhelm, O., Hafter, R., Henschen, A., Schmitt, M., and Graeff, H. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma. Blood 1990; 75: 1673–8.

    CAS  PubMed  Google Scholar 

  • Wilhelm, O., Schmitt, M., Hohl, S., Senekowitsch, R., and Graeff, H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296–302.

    Article  CAS  PubMed  Google Scholar 

  • Wilhelm, O., Weidle, U., Hohl, S., Rettenberger, P., Schmitt, M., and Graeff, H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994; 337: 131–4.

    Article  CAS  PubMed  Google Scholar 

  • Xu, F. J., Stack, S., Boyer, C., O’Briant, K., Whitaker, R., Mills, G. B., Yu, Y. H., and Bast, R. C., Jr. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 1997; 3: 1629–34.

    CAS  PubMed  Google Scholar 

  • Xu, Y., Fang, X. J., Casey, G., and Mills, G. B. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995; 309: 933–40.

    CAS  PubMed  Google Scholar 

  • Xu, Y., Gaudette, D. C., Boynton, J. D., Frankel, A., Fang, X. J., Sharma, A., Hurteau, J., Casey, G., Goodbody, A., Mellors, A., and et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients, Clin Cancer Res 1995; 1: 1223–32.

    CAS  PubMed  Google Scholar 

  • Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., Kennedy, A. W., Belinson, J., Markman, M., and Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers [see comments]. Jama 1998; 280: 719–23.

    Article  CAS  PubMed  Google Scholar 

  • Young, T. N., Rodriguez, G. C., Moser, T. L., Bast, R. C., Jr., Pizzo, S. V., and Stack, M. S. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol 1994; 170: 1285–96.

    CAS  PubMed  Google Scholar 

  • Young, T. N., Rodriguez, G. C., Rinehart, A. R., Bast, R. C., Jr., Pizzo, S. V., and Stack, M. S. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996; 62: 89–99.

    Article  CAS  PubMed  Google Scholar 

  • Young, T.N., Pizzo, S.V., Stack, M.S. A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J Biol Chem 1995; 270: 999–1002.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Cell & Molecular Biology and Obstetrics & Gynecology, Northwestern University Medical School, Chicago, IL, 60611, USA

    Supurna Ghosh, Yi Wu & M. Sharon Stack

Authors
  1. Supurna Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Sharon Stack
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ghosh, S., Wu, Y., Stack, M.S. (2002). Ovarian Cancer- Associated Proteinases. In: Ovarian Cancer. Cancer Treatment and Research, vol 107. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3587-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4757-3587-1_16

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4757-3589-5

  • Online ISBN: 978-1-4757-3587-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation